AU4025193A - Humanized C-erbB-2 specific antibodies - Google Patents

Humanized C-erbB-2 specific antibodies

Info

Publication number
AU4025193A
AU4025193A AU40251/93A AU4025193A AU4025193A AU 4025193 A AU4025193 A AU 4025193A AU 40251/93 A AU40251/93 A AU 40251/93A AU 4025193 A AU4025193 A AU 4025193A AU 4025193 A AU4025193 A AU 4025193A
Authority
AU
Australia
Prior art keywords
erbb
humanized
specific antibodies
antibodies
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU40251/93A
Inventor
Clayton Casipit
Sheng-Yung Chang
Mark De Boer
L.L. Houston
Hing C Wong
Lelia Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cetus Oncology Corp
Original Assignee
Cetus Oncology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Oncology Corp filed Critical Cetus Oncology Corp
Publication of AU4025193A publication Critical patent/AU4025193A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
AU40251/93A 1992-04-08 1993-04-01 Humanized C-erbB-2 specific antibodies Abandoned AU4025193A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86601992A 1992-04-08 1992-04-08
US866019 1992-04-08

Publications (1)

Publication Number Publication Date
AU4025193A true AU4025193A (en) 1993-11-18

Family

ID=25346755

Family Applications (1)

Application Number Title Priority Date Filing Date
AU40251/93A Abandoned AU4025193A (en) 1992-04-08 1993-04-01 Humanized C-erbB-2 specific antibodies

Country Status (2)

Country Link
AU (1) AU4025193A (en)
WO (1) WO1993021319A1 (en)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1997894B1 (en) * 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US6448077B1 (en) * 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US5861499A (en) 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
DK0896586T4 (en) * 1996-03-27 2015-08-24 Genentech Inc ErbB3 antibodies.
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
EP2042194A3 (en) 1999-05-14 2009-04-22 Imclone Systems, Inc. Treatment of refractory human tumors with epidermal growth factor receptor antagonists
CA2727172A1 (en) 1999-05-26 2001-01-04 Genentech, Inc. Methods of treatment using anti-erbb antibody-maytansinoid conjugates
BRPI0017590B8 (en) 1999-06-25 2021-05-25 Genentech Inc maytansinoid conjugate - anti-erbb antibody, and pharmaceutical formulation
KR20090126330A (en) 1999-08-27 2009-12-08 제넨테크, 인크. Dosages for treatment with anti-erbb2 antibodies
EP2266607A3 (en) 1999-10-01 2011-04-20 Immunogen, Inc. Immunoconjugates for treating cancer
AU2001227966A1 (en) * 2000-01-20 2001-07-31 Chiron Corporation Methods for treating tumors
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
JP2003531588A (en) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド Multivalent antibodies and their uses
US7071319B2 (en) 2000-05-16 2006-07-04 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
EP1282703B1 (en) 2000-05-16 2008-10-15 Thomas Jefferson University Rabies virus-specific neutralizing human monoclonal antibodies and nucleic acids and related methods
PL400669A1 (en) 2000-05-19 2012-11-05 Genentech, Inc. Genetic probe for detecting a response to ErbB antagonist for improving the likelihood and efficiency of cancer treatment
JP2005522514A (en) 2002-04-10 2005-07-28 ジェネンテック・インコーポレーテッド Modified anti-HER2 antibody
CN101711866A (en) 2002-07-15 2010-05-26 健泰科生物技术公司 Method for identifying tumors that are responsive to treatment with anti-ErbB2 antibodies
ES2534294T3 (en) 2002-07-19 2015-04-21 Beth Israel Deaconess Medical Center Methods to treat preeclampsia
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
US7638605B2 (en) 2003-05-01 2009-12-29 ImClone, LLC Fully human antibodies directed against the human insulin-like growth factor-1 receptor
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
BR122018071808B8 (en) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugate
CN103007279B (en) 2004-03-19 2017-01-11 英克隆有限责任公司 Human anti-epidermal growth factor receptor antibody
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
RU2361880C2 (en) 2004-07-22 2009-07-20 Дженентек, Инк. Composition of her2 antibodies
EP1784220B1 (en) 2004-08-26 2017-12-20 The University Of Western Ontario Bacterial iron acquisition targets
NZ580115A (en) 2004-09-23 2010-10-29 Genentech Inc Cysteine engineered antibody light chains and conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
CA2581336C (en) 2004-09-24 2022-10-04 S. Ananth Karumanchi Diagnosis of pregnancy-related hypertensive disorder by measurement of soluble endoglin
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
DK1819358T3 (en) 2004-11-18 2014-10-27 Imclone Llc Antibodies to Vascular Endothelial Growth Factor Receptor-1
EP1812064A4 (en) 2004-11-19 2009-07-08 Cornell Res Foundation Inc Use of vascular endothelial growth factor receptor 1+ cells in treating and monitoring cancer and in screening for chemotherapeutics
AU2005337873A1 (en) 2004-12-15 2007-05-10 Beth Israel Deaconess Medical Center Nucleic acids and polypeptides useful for diagnosing and treating complications of pregnancy
MX2007006895A (en) 2004-12-23 2007-06-26 Hoffmann La Roche Detection of a therapeutic antibody in an experimental animal.
PL1846030T3 (en) 2005-01-21 2019-05-31 Genentech Inc Fixed dosing of her antibodies
MX2007009889A (en) 2005-02-23 2007-09-07 Genentech Inc Extending time to disease progression or survival in cancer patients using a her dimerization inhibitor.
CA2612449A1 (en) 2005-06-17 2006-12-28 Imclone Systems Incorporated Receptor antagonists for treatment of metastatic bone cancer
MY157955A (en) 2005-07-06 2016-08-30 Hoffmann La Roche Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
US20070128184A1 (en) 2005-08-30 2007-06-07 Eckhard Podack Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists and immunotoxins
US7745584B2 (en) 2006-05-22 2010-06-29 California Institute Of Technology Antibodies to sulfated carbohydrates
KR101528939B1 (en) 2006-07-18 2015-06-15 사노피 Antagonist antibody against epha2 for the treatment of cancer
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2899541A1 (en) 2007-03-02 2015-07-29 Genentech, Inc. Predicting response to a HER dimerisation inhbitor based on low HER3 expression
WO2008118324A2 (en) 2007-03-26 2008-10-02 Macrogenics, Inc. Composition and method of treating cancer with an anti-uroplakin ib antibody
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
DK2171090T3 (en) 2007-06-08 2013-06-10 Genentech Inc Gene expression markers for tumor resistance to HER2 inhibitor therapy
KR100883430B1 (en) 2007-06-13 2009-02-12 한국생명공학연구원 Human Monoclonal Antibody Neutralizing Vesicular Endothelial Growth Factor Receptor and Use Thereof
WO2009032661A1 (en) 2007-08-29 2009-03-12 Sanofi-Aventis Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US8912149B1 (en) 2007-11-28 2014-12-16 California Institute Of Technology Glycosaminoglycan mimetics
TWI472339B (en) 2008-01-30 2015-02-11 Genentech Inc Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
NZ587305A (en) 2008-03-12 2012-05-25 Imclone Llc Anti-tyrosinase-realted protein-1 (TYRP1) antibodies
AR071891A1 (en) 2008-05-30 2010-07-21 Imclone Llc ANTI-FLT3 HUMAN ANTIBODIES (THIROSINE KINASE 3 RECEPTOR HUMAN FMS TYPE)
BRPI0812682A2 (en) 2008-06-16 2010-06-22 Genentech Inc metastatic breast cancer treatment
EP2303332B1 (en) 2008-07-15 2014-12-31 Genentech, Inc. Anthracycline conjugates, process for their preparation and their use as antitumor compounds
ES2549877T3 (en) 2008-09-07 2015-11-02 Glyconex Inc. Antiglucosphingolipid antibody of extended type I, derivatives thereof and use
CN102356092B (en) 2009-03-20 2014-11-05 霍夫曼-拉罗奇有限公司 Bispecific anti-HER antibodies
WO2010136569A1 (en) 2009-05-29 2010-12-02 F. Hoffmann-La Roche Ag Modulators for her2 signaling in her2 expressing patients with gastric cancer
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
EP2467492A4 (en) 2009-08-18 2013-01-09 Harvard College Methods and compositions for the treatment of proliferative and pathogenic diseases
AR078161A1 (en) 2009-09-11 2011-10-19 Hoffmann La Roche VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
TW201116297A (en) 2009-10-02 2011-05-16 Sanofi Aventis Antibodies that specifically bind to the EphA2 receptor
RU2580038C2 (en) 2009-12-04 2016-04-10 Дженентек, Инк. Multispecific antibodies, thereof analogues, compositions and methods
AU2011215900A1 (en) 2010-02-10 2012-07-26 Immunogen, Inc. CD20 antibodies and uses thereof
JP5981853B2 (en) 2010-02-18 2016-08-31 ジェネンテック， インコーポレイテッド Neuregulin antagonists and their use in the treatment of cancer
US9375473B2 (en) 2010-02-19 2016-06-28 Cornell Research Foundation, Inc. Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2011145085A2 (en) 2010-05-21 2011-11-24 Procognia (Israel) Ltd Novel antibodies and methods of use for the treatment and diagnosis of cancer
KR101839163B1 (en) 2010-06-08 2018-03-15 제넨테크, 인크. Cysteine engineered antibodies and conjugates
AR084469A1 (en) 2010-07-09 2013-05-22 Exelixis Inc COMBINATIONS OF QUINASE INHIBITORS FOR CANCER TREATMENT
MX360347B (en) 2010-08-17 2018-10-30 F Hoffmann La Roche Ag Star Anti-human igg1 antibody.
CA2816426A1 (en) 2010-11-17 2012-06-07 Genentech, Inc. Alaninyl maytansinol antibody conjugates
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
CA2820095C (en) 2010-12-21 2019-02-26 F. Hoffmann-La Roche Ag Isoform enriched antibody preparation and method for obtaining it
EP2655413B1 (en) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
PL3235508T3 (en) 2011-03-16 2021-07-12 Sanofi Compositions comprising a dual v region antibody-like protein
KR20140057326A (en) 2011-08-17 2014-05-12 제넨테크, 인크. Neuregulin antibodies and uses thereof
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
CA2857114A1 (en) 2011-11-30 2013-06-06 Genentech, Inc. Erbb3 mutations in cancer
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
CN104220457A (en) 2012-03-27 2014-12-17 霍夫曼-拉罗奇有限公司 Diagnosis and treatments relating to her3 inhibitors
US11142762B2 (en) 2012-07-05 2021-10-12 The Trustees Of The University Of Pennsylvania U1 snRNP regulates gene expression and modulates oncogenicity
US9937205B2 (en) 2012-09-04 2018-04-10 The Trustees Of The University Of Pennsylvania Inhibition of diacylglycerol kinase to augment adoptive T cell transfer
KR102460297B1 (en) 2012-10-30 2022-10-28 에스퍼란스 파마슈티컬스, 인코포레이티드 Antibody/drug conjugates and methods of use
RU2692773C2 (en) 2012-11-30 2019-06-27 Ф.Хоффманн-Ля Рош Аг Identification of patients in need of combined therapy with pd-l1 inhibitor
WO2014182970A1 (en) 2013-05-08 2014-11-13 Zymeworks Inc. Bispecific her2 and her3 antigen binding constructs
US10227370B2 (en) 2013-08-02 2019-03-12 California Institute Of Technology Heparan sulfate/heparin mimetics with anti-chemokine and anti-inflammatory activity
US9770461B2 (en) 2013-08-02 2017-09-26 California Institute Of Technology Tailored glycopolymers as anticoagulant heparin mimetics
CN105940113A (en) 2013-11-13 2016-09-14 酵活有限公司 Monovalent antigen binding constructs targeting egfr and/or her2 and uses thereof
CN105980409B (en) 2013-11-27 2023-07-18 酵活生物制药有限公司 Bispecific antigen binding constructs targeting HER2
TWI745962B (en) 2014-06-27 2021-11-11 法商賽諾菲公司 Methods of determining whether a dose comprising a dual-v-region antibody-like protein or a fragment thereof administered to a human subject specifically binds to il-4 or il-13 within the human subject
KR20170052600A (en) 2014-09-12 2017-05-12 제넨테크, 인크. Cysteine engineered antibodies and conjugates
US20170355755A1 (en) 2014-11-21 2017-12-14 Yale University Compositions and methods for modulating salm5 and hvem
MA41629A (en) 2015-03-04 2018-01-09 Center For Human Reproduction COMPOSITIONS AND METHODS OF USE OF ANTI-MÜLLERIAN HORMONE FOR THE TREATMENT OF INFERTILITY
KR102647100B1 (en) 2015-05-30 2024-03-13 몰레큘러 템플레이츠, 인코퍼레이션. Deimmunized Shiga toxin A subunit scaffolds and cell-targeting molecules comprising the same
CN106729743B (en) 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 anti-ErbB 2 antibody-drug conjugate, and composition, preparation method and application thereof
EP3454863A1 (en) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
US10316037B1 (en) 2016-11-04 2019-06-11 Yale University Compounds and methods for treating cancer
WO2018129029A1 (en) 2017-01-04 2018-07-12 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
TWI808963B (en) 2017-03-22 2023-07-21 法商賽諾菲公司 Treatment of lupus using humanized anti-cxcr5 antibodies
KR20200143634A (en) 2018-04-17 2020-12-24 몰레큘러 템플레이츠, 인코퍼레이션. HER2-targeting molecule comprising deimmunized Shiga Toxin A subunit scaffold
EP3560945A1 (en) 2018-04-27 2019-10-30 F. Hoffmann-La Roche AG Methods for purification of polypeptides using polysorbates
US20210230255A1 (en) 2018-04-27 2021-07-29 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
WO2019217450A1 (en) 2018-05-08 2019-11-14 Rhode Island Hospital Anti-chi3l1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatohepatitis and subsequent complications
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
EP3976181A1 (en) 2019-05-24 2022-04-06 Sanofi Methods for treating systemic sclerosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
DE68924979T2 (en) * 1988-04-18 1996-10-24 Oncogene Science Inc DETECTION OF THE EXPRESSION OF NEW GENES AND PRODUCTS.

Also Published As

Publication number Publication date
WO1993021319A1 (en) 1993-10-28

Similar Documents

Publication Publication Date Title
AU4025193A (en) Humanized C-erbB-2 specific antibodies
AU4618193A (en) Humanized antibodies
AU4042195A (en) Anti-alphaV-integrin monoclonal antibody
HU9601574D0 (en) Humanized antibodies and uses thereof
AU3811495A (en) Antibodies
EP0627932A4 (en) Novel antibody construct.
AU7411896A (en) Bispecific antibody heterodimers
AU5869596A (en) Anti-gp130 monoclonal antibodies
AU5283893A (en) Recombinant humanized anti-cytomegalovirus antibodies
EP0671951A4 (en) Humanized antibodies reactive with l-selectin.
AU1289795A (en) Monoclonal antibodies specific for human interleukin-5
AU7041996A (en) Antibody specific for beta1->6N- acetylglucosamininyltransferase
AU6080794A (en) Antibodies directed against binding-associated epitopes
AU3459593A (en) Humanised antibody against hepatitis
AU6702998A (en) Anti-alphabeta3 humanized monoclonal antibodies
AU5732694A (en) Humanized antibodies reactive with cd18
EP0578515A3 (en) Humanized monoclonal antibodies.
GB9412166D0 (en) Retargetting antibodies
AU3330689A (en) Monoclonal antibodies
AU6155896A (en) Humanized antibodies to e-selectin
AU6725190A (en) Anti-platelet monoclonal antibody
EP0506523A3 (en) Monoclonal antibodies
AU1025692A (en) Novel chimeric antiidiotypic monoclonal antibodies
AU4195793A (en) Bispecific antibody
EP0586026A3 (en) Characterization of a novel anti-p110RB monoclonal antibody.